Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SRNE

3 Stocks Under $2 That Will More Than Double in the Next 12 Months, According to Wall Street

Surging inflation, interest rate hikes, and geopolitical uncertainties have recently put the stock market under pressure. So, it could be wise to bet on low-priced stocks that possess solid rebound prospects. Wall Street Analysts expect low-priced stocks PaySign, Inc. (PAYS), Sorrento Therapeutics, Inc. (SRNE), and National CineMedia, Inc. (NCMI) to…

StockNews.com · May 27, 2022

Sorrento's Scilex Unit Begins Mid-stage Study of Lower Back Pain Drug

Scilex Holding Company, a Sorrento Company (NASDAQ: SRNE) announced dosing of the first patient in a Phase 2 study of its drug candidate in patients with SP-103 in subjects with acute low back pain (LBP).

Benzinga · May 18, 2022

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Benzinga · May 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron

The FDA has cleared Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers. STI-9167 is the IV formulation of the intranasal STI-9199 neutralizing antibody. Also Read: Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients. The Phase 1 study…

Benzinga · Apr 25, 2022

Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) Phase 3 trial of abivertinib in severe COVID-19 patients. The clinical trial will be conducted in 2 phases, and the initial run-in will define the recommended Phase 3 Dose. In October last year, Sorrento released preliminary results of two phase 2 studies that seemed to show…

Benzinga · Mar 31, 2022

Sorrento's Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants

Sorrento Therapeutics Inc (NASDAQ:SRNE) announced the publication of a preprint entitled "Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta." Serum collected from omicron-specific mRNA vaccine immunized animals provided superior protection against the infection of omicron strain, including the BA.1, BA.1+R346K, and the more recent BA.2 sublineage. The data demonstrated…

Benzinga · Mar 21, 2022

Sorrento's Pain Company Reveals Final Results For SP-102 Data For Sciatica Pain Management

Sorrento Therapeutics Inc's (NASDAQ: SRNE) subsidiary Scilex Holding Company has announced final results from its SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program. SP-102 (Semdexa) has received Fast Track status from the FDA.

Benzinga · Mar 18, 2022

Read news from The Economist, FT, and more,
with one subscription

Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron

Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558,

Benzinga · Jan 28, 2022

Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant

Sorrento Therapeutics Inc (NASDAQ: SRNE) has

Benzinga · Jan 20, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.